MAYNE PHARMA APPOINTS NEW DIRECTOR
4 October 2021, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Carolyn Myers, M.B.A., Ph.D. has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately. Dr. Myers was nominated by Mayne Pharma's 9.6% shareholder, Mithra Pharmaceuticals SA, as required under the license and supply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the United States.
Dr. Myers, a US resident, is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen- repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies.
Mayne Pharma's Chair Mr Frank Condella said, "We are delighted to welcome Carolyn to the Board of Mayne Pharma. Carolyn has a distinguished track record of success in creating, growing, and leading health care businesses. She has deep experience in business development, sales and marketing, strategy, portfolio management and R&D and has led the launch of over 20 brand products."
Commenting on her appointment, Dr. Myers said, "I am pleased to be joining the Board at this important time in Mayne Pharma's development. As nominee of the Company's largest shareholder, our interests are aligned. I am committed to supporting the successful commercialisation of NEXTSTELLIS oral contraceptive in the world's largest pharmaceutical market."
Dr. Myers is a Steering Committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals. She has a Ph.D. from the University of British Columbia and a Masters in Business Administration from Rutgers University.
For further information contact:
Lisa Pendlebury (VP Investor Relations & Communications) +61 419 548 434, email@example.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.
Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world.
Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, NC, US with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.
Mayne Pharma Group Limited published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2021 07:55:33 UTC.